Line 3: |
Line 3: |
| |+WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Content | | |+WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Content |
| |- | | |- |
− | !'''Disease'''!!'''Page Type'''!!'''Author (Date Assigned)'''!!'''Associate Editor''' | + | !'''Disease'''!!'''Page Type'''!!'''Author''' |
| + | !'''Date Assigned'''!!'''Associate Editor''' |
| !Author Content Pending or Complete (Date Completed) | | !Author Content Pending or Complete (Date Completed) |
| !Editor Reviewed (Date) | | !Editor Reviewed (Date) |
Line 9: |
Line 10: |
| |- | | |- |
| |'''''Myeloproliferative Neoplasms (MPN)'''''||'''''Overview'''''||Mark Evans (trainee), Fabiola Quintero-Rivera | | |'''''Myeloproliferative Neoplasms (MPN)'''''||'''''Overview'''''||Mark Evans (trainee), Fabiola Quintero-Rivera |
| + | | |
| |Fabiola Quintero-Rivera (FQR) | | |Fabiola Quintero-Rivera (FQR) |
| |PENDING | | |PENDING |
Line 16: |
Line 18: |
| | Chronic Myeloid Leukemia (CML), BCR-ABL1-Positive||Disease | | | Chronic Myeloid Leukemia (CML), BCR-ABL1-Positive||Disease |
| |Mark Evans (trainee)+Jack Reid (trainee)+Fabiola Quintero-Rivera | | |Mark Evans (trainee)+Jack Reid (trainee)+Fabiola Quintero-Rivera |
| + | | |
| |FQR | | |FQR |
| |Complete | | |Complete |
Line 23: |
Line 26: |
| | Chronic Neutrophilic Leukemia (CNL)||Disease | | | Chronic Neutrophilic Leukemia (CNL)||Disease |
| |Anamaria Munteanu (trainee)+Fabiola Quintero-Rivera | | |Anamaria Munteanu (trainee)+Fabiola Quintero-Rivera |
| + | | |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
Line 30: |
Line 34: |
| | Polycythaemia Vera (PV)||Disease | | | Polycythaemia Vera (PV)||Disease |
| |Gokce A. Toruner | | |Gokce A. Toruner |
| + | | |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
Line 37: |
Line 42: |
| | Primary Myelofibrosis (PMF)||Disease | | | Primary Myelofibrosis (PMF)||Disease |
| |T. Niroshi Senaratne | | |T. Niroshi Senaratne |
| + | | |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
Line 44: |
Line 50: |
| | Essential Thrombocythaemia (ET)||Disease | | | Essential Thrombocythaemia (ET)||Disease |
| |Rebecca Smith (trainee) + faculty TBD | | |Rebecca Smith (trainee) + faculty TBD |
| + | | |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
Line 51: |
Line 58: |
| | Chronic Eosinophilic Leukemia, Not Otherwise Specified||Disease | | | Chronic Eosinophilic Leukemia, Not Otherwise Specified||Disease |
| |Mark Evans (trainee), Fabiola Quintero-Rivera | | |Mark Evans (trainee), Fabiola Quintero-Rivera |
| + | | |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
Line 58: |
Line 66: |
| | Myeloproliferative Neoplasm (MPN), Unclassifiable||Disease | | | Myeloproliferative Neoplasm (MPN), Unclassifiable||Disease |
| |Mark Evans (trainee)+ Fabiola Quintero-Rivera | | |Mark Evans (trainee)+ Fabiola Quintero-Rivera |
| + | | |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
Line 63: |
Line 72: |
| | | | | |
| |- | | |- |
− | |'''''Mastocytosis'''''||'''''Overview'''''|| ||FQR | + | |'''''Mastocytosis'''''||'''''Overview'''''|| |
| + | | ||FQR |
| | | | | |
| | | | | |
Line 70: |
Line 80: |
| | Cutaneous Mastocytosis||Disease | | | Cutaneous Mastocytosis||Disease |
| |Thuy Phung | | |Thuy Phung |
| + | | |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
Line 77: |
Line 88: |
| | Systemic Mastocytosis||Disease | | | Systemic Mastocytosis||Disease |
| |Shashi Shetty | | |Shashi Shetty |
| + | | |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
Line 84: |
Line 96: |
| | Mast Cell Sarcoma||Disease | | | Mast Cell Sarcoma||Disease |
| |Thuy Phung | | |Thuy Phung |
| + | | |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
Line 90: |
Line 103: |
| |- | | |- |
| |'''''Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2'''''||'''''Overview'''''||Daynna J.Wolff | | |'''''Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2'''''||'''''Overview'''''||Daynna J.Wolff |
| + | | |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
Line 96: |
Line 110: |
| |- | | |- |
| | Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement||Disease||Jay Alden (trainee) +Daynna J.Wolff | | | Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement||Disease||Jay Alden (trainee) +Daynna J.Wolff |
| + | | |
| |FQR | | |FQR |
| |Complete | | |Complete |
Line 102: |
Line 117: |
| |- | | |- |
| | Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement||Disease||Christopher Sullivan (trainee) + Daynna J.Wolff | | | Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement||Disease||Christopher Sullivan (trainee) + Daynna J.Wolff |
| + | | |
| |FQR | | |FQR |
| |Complete | | |Complete |
Line 108: |
Line 124: |
| |- | | |- |
| | Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement||Disease||Yanna Ding | | | Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement||Disease||Yanna Ding |
| + | | |
| |FQR | | |FQR |
| |Complete | | |Complete |
Line 114: |
Line 131: |
| |- | | |- |
| | Myeloid/Lymphoid Neoplasms with PCM1-JAK2||Disease||Jessica Snider (trainee) + Daynna J.Wolff | | | Myeloid/Lymphoid Neoplasms with PCM1-JAK2||Disease||Jessica Snider (trainee) + Daynna J.Wolff |
| + | | |
| |FQR | | |FQR |
| |Complete | | |Complete |
Line 122: |
Line 140: |
| |Disease | | |Disease |
| |Lauren R. Crowson (trainee)-Hindman + Daynna J. Wolff | | |Lauren R. Crowson (trainee)-Hindman + Daynna J. Wolff |
| + | | |
| |FQR | | |FQR |
| |Complete | | |Complete |
Line 130: |
Line 149: |
| |Disease | | |Disease |
| |Lauren R. Crowson (trainee) + Daynna J. Wolff | | |Lauren R. Crowson (trainee) + Daynna J. Wolff |
| + | | |
| |FQR | | |FQR |
| |Complete | | |Complete |
Line 136: |
Line 156: |
| |- | | |- |
| |'''''Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)'''''||'''''Overview'''''||Linsheng Zhang | | |'''''Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)'''''||'''''Overview'''''||Linsheng Zhang |
| + | | |
| |FQR | | |FQR |
| |Complete | | |Complete |
Line 142: |
Line 163: |
| |- | | |- |
| | Chronic Myelomonocytic Leukemia (CMML)||Disease||Linsheng Zhang | | | Chronic Myelomonocytic Leukemia (CMML)||Disease||Linsheng Zhang |
| + | | |
| |FQR | | |FQR |
| |Complete | | |Complete |
Line 148: |
Line 170: |
| |- | | |- |
| | Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative||Disease||Linsheng Zhang | | | Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative||Disease||Linsheng Zhang |
| + | | |
| |FQR | | |FQR |
| |Complete | | |Complete |
Line 154: |
Line 177: |
| |- | | |- |
| | Juvenile Myelomonocytic Leukemia (JMML)||Disease||Sarah Rapisardo | | | Juvenile Myelomonocytic Leukemia (JMML)||Disease||Sarah Rapisardo |
| + | | |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
Line 160: |
Line 184: |
| |- | | |- |
| | Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)||Disease||Anamaria Munteanu (trainee)+Fabiola Quintero-Rivera | | | Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)||Disease||Anamaria Munteanu (trainee)+Fabiola Quintero-Rivera |
| + | | |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
Line 166: |
Line 191: |
| |- | | |- |
| | Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable||Disease||Ruth MacKinnon | | | Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable||Disease||Ruth MacKinnon |
| + | | |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
Line 172: |
Line 198: |
| |- | | |- |
| |'''''Myelodysplastic Syndromes (MDS)'''''||'''''Overview'''''||Teresa Smolarek? | | |'''''Myelodysplastic Syndromes (MDS)'''''||'''''Overview'''''||Teresa Smolarek? |
| + | | |
| |FQR | | |FQR |
| | | | | |
Line 178: |
Line 205: |
| |- | | |- |
| | Myelodysplastic Syndrome (MDS) with Single Lineage Dysplasia||Disease||Xiaoli Du(trainee) +Teresa Smolarek | | | Myelodysplastic Syndrome (MDS) with Single Lineage Dysplasia||Disease||Xiaoli Du(trainee) +Teresa Smolarek |
| + | | |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
Line 184: |
Line 212: |
| |- | | |- |
| | Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS)||Disease||Xiaolin Hu(trainee)+Teresa Smolarek | | | Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS)||Disease||Xiaolin Hu(trainee)+Teresa Smolarek |
| + | | |
| |FQR | | |FQR |
| |Complete | | |Complete |
Line 190: |
Line 219: |
| |- | | |- |
| | Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia||Disease||Xiaolin Hu(trainee)+Teresa Smolarek | | | Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia||Disease||Xiaolin Hu(trainee)+Teresa Smolarek |
| + | | |
| |FQR | | |FQR |
| |Complete | | |Complete |
Line 196: |
Line 226: |
| |- | | |- |
| | Myelodysplastic syndrome with multilineage dysplasiaMyelodysplastic Syndrome (MDS) with Multilineage Dysplasia||Disease||Xiaoli Du(trainee)+Teresa Smolarek | | | Myelodysplastic syndrome with multilineage dysplasiaMyelodysplastic Syndrome (MDS) with Multilineage Dysplasia||Disease||Xiaoli Du(trainee)+Teresa Smolarek |
| + | | |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
Line 202: |
Line 233: |
| |- | | |- |
| | Myelodysplastic Syndrome (MDS) with Excess Blasts||Disease||Xiaoli Du(trainee)+Teresa Smolarek | | | Myelodysplastic Syndrome (MDS) with Excess Blasts||Disease||Xiaoli Du(trainee)+Teresa Smolarek |
| + | | |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
Line 208: |
Line 240: |
| |- | | |- |
| | Myelodysplastic Syndrome (MDS) with Isolated del(5q)||Disease||Xiaolin Hu(trainee)+Teresa Smolarek | | | Myelodysplastic Syndrome (MDS) with Isolated del(5q)||Disease||Xiaolin Hu(trainee)+Teresa Smolarek |
| + | | |
| |FQR | | |FQR |
| |Complete | | |Complete |
Line 214: |
Line 247: |
| |- | | |- |
| | Myelodysplastic Syndrome (MDS), Unclassifiable||Disease||Xiaolin Hu(trainee)+Teresa Smolarek | | | Myelodysplastic Syndrome (MDS), Unclassifiable||Disease||Xiaolin Hu(trainee)+Teresa Smolarek |
| + | | |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
Line 220: |
Line 254: |
| |- | | |- |
| | Refractory Cytopenia of Childhood||Disease||Xiaoli Du(trainee)+Teresa Smolarek | | | Refractory Cytopenia of Childhood||Disease||Xiaoli Du(trainee)+Teresa Smolarek |
| + | | |
| |FQR | | |FQR |
| |PENDING | | |PENDING |
Line 225: |
Line 260: |
| | | | | |
| |- | | |- |
− | | || || || | + | | || || |
| + | | || |
| | | | | |
| | | | | |
Line 231: |
Line 267: |
| |- | | |- |
| |'''''Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms'''''||'''''Overview'''''||Daynna Wolff+Daniel Butler (Path Resident) | | |'''''Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms'''''||'''''Overview'''''||Daynna Wolff+Daniel Butler (Path Resident) |
| + | | |
| |Jennelle Hodge (JH)/ Malini Sathanoori (MS) | | |Jennelle Hodge (JH)/ Malini Sathanoori (MS) |
| |Complete | | |Complete |
Line 236: |
Line 273: |
| | | | | |
| |- | | |- |
− | |'''''Myeloid Neoplasms with Germline Predisposition'''''||'''''Overview'''''||Ying Zou||JH / MS | + | |'''''Myeloid Neoplasms with Germline Predisposition'''''||'''''Overview'''''||Ying Zou |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| | | | | |
| |- | | |- |
− | | Acute Myeloid Leukaemia with Germline CEBPA Mutation||Disease||Daynna Wolff+Matthew Kilpatrick (Path Resident)||JH / MS | + | | Acute Myeloid Leukaemia with Germline CEBPA Mutation||Disease||Daynna Wolff+Matthew Kilpatrick (Path Resident) |
| + | | ||JH / MS |
| |PENDING | | |PENDING |
| | | | | |
| | | | | |
| |- | | |- |
− | | Myeloid Neoplasms with Germline DDX41 Mutation||Disease||Fei Yang||JH / MS | + | | Myeloid Neoplasms with Germline DDX41 Mutation||Disease||Fei Yang |
| + | | ||JH / MS |
| |PENDING | | |PENDING |
| | | | | |
| | | | | |
| |- | | |- |
− | | Myeloid Neoplasms with Germline RUNX1 Mutation||Disease||Malini Sathanoori||JH / MS | + | | Myeloid Neoplasms with Germline RUNX1 Mutation||Disease||Malini Sathanoori |
| + | | ||JH / MS |
| |PENDING | | |PENDING |
| | | | | |
| | | | | |
| |- | | |- |
− | | Myeloid Neoplasms with Germline ANKRD26 Mutation||Disease||Fei Yang||JH / MS | + | | Myeloid Neoplasms with Germline ANKRD26 Mutation||Disease||Fei Yang |
| + | | ||JH / MS |
| |PENDING | | |PENDING |
| | | | | |
| | | | | |
| |- | | |- |
− | | Myeloid Neoplasms with Germline ETV6 Mutation||Disease||Ying Zou||JH / MS | + | | Myeloid Neoplasms with Germline ETV6 Mutation||Disease||Ying Zou |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| | | | | |
| |- | | |- |
− | | Myeloid Neoplasms with Germline GATA2 Mutation||Disease||Daynna Wolff+ Alexandria Avery (Path Resident)||JH / MS | + | | Myeloid Neoplasms with Germline GATA2 Mutation||Disease||Daynna Wolff+ Alexandria Avery (Path Resident) |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
Line 272: |
Line 316: |
| |- | | |- |
| |'''''Acute Myeloid Leukemia (AML) with Recurrent Genetic Abnormalities'''''||'''''Overview'''''||Daynna Wolff+ Dan Wang (trainee) | | |'''''Acute Myeloid Leukemia (AML) with Recurrent Genetic Abnormalities'''''||'''''Overview'''''||Daynna Wolff+ Dan Wang (trainee) |
| + | | |
| |JH / MS | | |JH / MS |
| |Complete | | |Complete |
Line 277: |
Line 322: |
| | | | | |
| |- | | |- |
− | | Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1||Disease||Christine Bryke||JH / MS | + | | Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1||Disease||Christine Bryke |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| | | | | |
| |- | | |- |
− | | Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11||Disease||Christine Bryke||JH / MS | + | | Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11||Disease||Christine Bryke |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| | | | | |
| |- | | |- |
− | | Acute Promyelocytic Leukemia (APL) with PML-RARA||Disease||Shashi Shetty||JH / MS | + | | Acute Promyelocytic Leukemia (APL) with PML-RARA||Disease||Shashi Shetty |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| | | | | |
| |- | | |- |
− | | Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3||Disease||Shashi Shetty||JH / MS | + | | Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3||Disease||Shashi Shetty |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| | | | | |
| |- | | |- |
− | | Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214||Disease||Jennelle Hodge||JH / MS | + | | Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214||Disease||Jennelle Hodge |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| | | | | |
| |- | | |- |
− | | Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM||Disease||Gordana Raca||JH / MS | + | | Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM||Disease||Gordana Raca |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| |Need permission for figure? Update WHO? | | |Need permission for figure? Update WHO? |
| |- | | |- |
− | | Acute Myeloid Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1||Disease||Jennelle Hodge||JH / MS | + | | Acute Myeloid Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1||Disease||Jennelle Hodge |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| | | | | |
| |- | | |- |
− | | Acute Myeloid Leukemia (AML) with BCR-ABL1||Disease||Kay Weng Choy + Greg Conboy (Monash Health)||JH / MS | + | | Acute Myeloid Leukemia (AML) with BCR-ABL1||Disease||Kay Weng Choy + Greg Conboy (Monash Health) |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| | | | | |
| |- | | |- |
− | | Acute Myeloid Leukemia (AML) with Mutated NPM1||Disease||Xinjie Xu+Kay Weng Choy + Greg Conboy (Monash Health)||JH / MS | + | | Acute Myeloid Leukemia (AML) with Mutated NPM1||Disease||Xinjie Xu+Kay Weng Choy + Greg Conboy (Monash Health) |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| |Add WHO reference | | |Add WHO reference |
| |- | | |- |
− | | Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA||Disease||Paul deFazio, MSc + Greg Conboy (Monash Health)||JH / MS | + | | Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA||Disease||Paul deFazio, MSc + Greg Conboy (Monash Health) |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| | | | | |
| |- | | |- |
− | | Acute Myeloid Leukemia (AML) with Mutated RUNX1||Disease||Daynna Wolff+Iris Martin (Path Resident)||JH / MS | + | | Acute Myeloid Leukemia (AML) with Mutated RUNX1||Disease||Daynna Wolff+Iris Martin (Path Resident) |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| | | | | |
| |- | | |- |
− | |Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes||Disease||Fei Yang||JH / MS | + | |Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes||Disease||Fei Yang |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| | | | | |
| |- | | |- |
− | |Therapy-Related Myeloid Neoplasms||Disease||Shashi Shetty + Shawn A. Silver (resident)||JH / MS | + | |Therapy-Related Myeloid Neoplasms||Disease||Shashi Shetty + Shawn A. Silver (resident) |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| |Check reference format | | |Check reference format |
| |- | | |- |
− | |''Acute Myeloid Leukemia (AML), Not Otherwise Specified''||'''''Overview'''''||Anwar Iqbal||JH / MS | + | |''Acute Myeloid Leukemia (AML), Not Otherwise Specified''||'''''Overview'''''||Anwar Iqbal |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| | | | | |
| |- | | |- |
− | | Acute Myeloid Leukemia (AML) with Minimal Differentiation||Disease||Fabiola Quintero-Rivera and Celeste Eno (fellow)||JH / MS | + | | Acute Myeloid Leukemia (AML) with Minimal Differentiation||Disease||Fabiola Quintero-Rivera and Celeste Eno (fellow) |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| | | | | |
| |- | | |- |
− | | Acute Myeloid Leukemia (AML) without Maturation||Disease||Jennelle Hodge||JH / MS | + | | Acute Myeloid Leukemia (AML) without Maturation||Disease||Jennelle Hodge |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| | | | | |
| |- | | |- |
− | | Acute Myeloid Leukemia (AML) with Maturation||Disease||Jennelle Hodge||JH / MS | + | | Acute Myeloid Leukemia (AML) with Maturation||Disease||Jennelle Hodge |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| | | | | |
| |- | | |- |
− | | Acute Myelomonocytic Leukemia||Disease||Fei Yang||JH / MS | + | | Acute Myelomonocytic Leukemia||Disease||Fei Yang |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| | | | | |
| |- | | |- |
− | | Acute Monoblastic and Monocytic Leukemia||Disease||Fei Yang||JH / MS | + | | Acute Monoblastic and Monocytic Leukemia||Disease||Fei Yang |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| | | | | |
| |- | | |- |
− | | Pure Erythroid Leukemia||Disease||Ash Yenamandra||JH / MS | + | | Pure Erythroid Leukemia||Disease||Ash Yenamandra |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| | | | | |
| |- | | |- |
− | | Acute Megakaryoblastic Leukemia (AMKL)||Disease||Fei Yang||JH / MS | + | | Acute Megakaryoblastic Leukemia (AMKL)||Disease||Fei Yang |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| | | | | |
| |- | | |- |
− | | Acute Basophilic Leukemia||Disease||Ash Yenamandra||JH / MS | + | | Acute Basophilic Leukemia||Disease||Ash Yenamandra |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| | | | | |
| |- | | |- |
− | | Acute Panmyelosis with Myelofibrosis||Disease||Ying Zou and Jialing Huang (MGP fellow)||JH / MS | + | | Acute Panmyelosis with Myelofibrosis||Disease||Ying Zou and Jialing Huang (MGP fellow) |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| | | | | |
| |- | | |- |
− | |Myeloid Sarcoma||Disease||Fabiola Quintero-Rivera||JH / MS | + | |Myeloid Sarcoma||Disease||Fabiola Quintero-Rivera |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| | | | | |
| |- | | |- |
− | |'''''Myeloid Proliferations Associated with Down Syndrome'''''||'''''Overview'''''||Patty Greipp||JH / MS | + | |'''''Myeloid Proliferations Associated with Down Syndrome'''''||'''''Overview'''''||Patty Greipp |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| |Need permission for figure? | | |Need permission for figure? |
| |- | | |- |
− | | Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome||Disease||Linda Cooley||JH / MS | + | | Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome||Disease||Linda Cooley |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| | | | | |
| |- | | |- |
− | | Myeloid Leukemia Associated with Down Syndrome||Disease||Linda Cooley||JH / MS | + | | Myeloid Leukemia Associated with Down Syndrome||Disease||Linda Cooley |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| | | | | |
| |- | | |- |
− | |Blastic Plasmacytoid Dendritic Cell Neoplasm||Disease||Daynna Wolff+Hao Liu (Path Resident)||JH / MS | + | |Blastic Plasmacytoid Dendritic Cell Neoplasm||Disease||Daynna Wolff+Hao Liu (Path Resident) |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| | | | | |
| |- | | |- |
− | |'''''Acute Leukemias of Ambiguous Lineage'''''||'''''Overview'''''||Hui Chen/ Jennelle Hodge||JH / MS | + | |'''''Acute Leukemias of Ambiguous Lineage'''''||'''''Overview'''''||Hui Chen/ Jennelle Hodge |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| | | | | |
| |- | | |- |
− | | Acute Undifferentiated Leukemia||Disease||Shashi Shetty + Amelia Nakanishi (resident)||JH / MS | + | | Acute Undifferentiated Leukemia||Disease||Shashi Shetty + Amelia Nakanishi (resident) |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| |Check reference format | | |Check reference format |
| |- | | |- |
− | | Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1||Disease||Tracy Tucker||JH / MS | + | | Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1||Disease||Tracy Tucker |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| | | | | |
| |- | | |- |
− | | Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged||Disease||Tracy Tucker||JH / MS | + | | Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged||Disease||Tracy Tucker |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| | | | | |
| |- | | |- |
− | | Mixed Phenotype Acute Leukemia (MPAL), B/Myeloid, Not Otherwise Specified||Disease||Shashi Shetty + Priyatharsini Nirmalanantham (resident)||JH / MS | + | | Mixed Phenotype Acute Leukemia (MPAL), B/Myeloid, Not Otherwise Specified||Disease||Shashi Shetty + Priyatharsini Nirmalanantham (resident) |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| |Check reference format | | |Check reference format |
| |- | | |- |
− | | Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified||Disease||Fabiola Quintero-Rivera||JH / MS | + | | Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified||Disease||Fabiola Quintero-Rivera |
| + | | ||JH / MS |
| |Complete | | |Complete |
| | | | | |
| | | | | |
| |- | | |- |
− | | ??Mixed-Phenotype Acute Leukaemia, Not Otherwise Specified (NOS), Rare Types||Disease|| ||JH / MS | + | | ??Mixed-Phenotype Acute Leukaemia, Not Otherwise Specified (NOS), Rare Types||Disease|| |
| + | | ||JH / MS |
| |?? | | |?? |
| | | | | |
| | | | | |
| |- | | |- |
− | | ??Acute Leukaemias of Ambiguous Lineage, Not Otherwise Specified (NOS)||Disease|| ||JH / MS | + | | ??Acute Leukaemias of Ambiguous Lineage, Not Otherwise Specified (NOS)||Disease|| |
| + | | ||JH / MS |
| |?? | | |?? |
| | | | | |
Line 460: |
Line 541: |
| |Disease | | |Disease |
| |Kay Weng Choy + Greg Conboy (Monash Health) | | |Kay Weng Choy + Greg Conboy (Monash Health) |
| + | | |
| |JH / MS | | |JH / MS |
| |Complete | | |Complete |
Line 468: |
Line 550: |
| |Disease | | |Disease |
| |Daynna Wolff+Jessica Snider (Path Resident) | | |Daynna Wolff+Jessica Snider (Path Resident) |
| + | | |
| |JH / MS | | |JH / MS |
| |PENDING | | |PENDING |
Line 476: |
Line 559: |
| |Disease | | |Disease |
| |Daynna Wolff+ Paige Woodham (Path Resident) | | |Daynna Wolff+ Paige Woodham (Path Resident) |
| + | | |
| |JH / MS | | |JH / MS |
| |PENDING | | |PENDING |
Line 481: |
Line 565: |
| |NON-WHO ENTITY | | |NON-WHO ENTITY |
| |- | | |- |
− | | || || || | + | | || || |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |'''''Precursor Lymphoid Neoplasms'''''||'''''Overview'''''|| ||Yassmine Akkari (YA) | + | |'''''Precursor Lymphoid Neoplasms'''''||'''''Overview'''''|| |
| + | | ||Yassmine Akkari (YA) |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |'''''B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities'''''||'''''Overview'''''|| ||YA | + | |'''''B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities'''''||'''''Overview'''''|| |
| + | | ||YA |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1 ||Disease|| ||YA | + | | B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1 ||Disease|| |
| + | | ||YA |
| | | | | |
| | | | | |
Line 502: |
Line 590: |
| |- | | |- |
| | B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged||Disease||Yassmine Akkari+Nicolas Millan (trainee) | | | B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged||Disease||Yassmine Akkari+Nicolas Millan (trainee) |
| + | | |
| |YA | | |YA |
| |PENDING | | |PENDING |
Line 507: |
Line 596: |
| | | | | |
| |- | | |- |
− | | B-Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1||Disease|| ||YA | + | | B-Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1||Disease|| |
| + | | ||YA |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy||Disease|| ||YA | + | | B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy||Disease|| |
| + | | ||YA |
| | | | | |
| | | | | |
Line 520: |
Line 611: |
| | | |
| Lisa Smith + Yassmine Akkari | | Lisa Smith + Yassmine Akkari |
| + | | |
| |YA | | |YA |
| |Complete | | |Complete |
Line 525: |
Line 617: |
| | | | | |
| |- | | |- |
− | | B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3||Disease|| ||YA | + | | B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3||Disease|| |
| + | | ||YA |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1||Disease|| ||YA | + | | B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1||Disease|| |
| + | | ||YA |
| | | | | |
| | | | | |
Line 536: |
Line 630: |
| |- | | |- |
| | B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like||Disease||Mark G. Evans + Fabiola Quintero-Rivera | | | B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like||Disease||Mark G. Evans + Fabiola Quintero-Rivera |
| + | | |
| |YA | | |YA |
| |Complete | | |Complete |
Line 541: |
Line 636: |
| | | | | |
| |- | | |- |
− | | B-Lymphoblastic Leukemia/Lymphoma with iAMP21||Disease|| ||YA | + | | B-Lymphoblastic Leukemia/Lymphoma with iAMP21||Disease|| |
| + | | ||YA |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified||Disease|| ||YA | + | | B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified||Disease|| |
| + | | ||YA |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |'''''T-Lymphoblastic Leukemia/Lymphoma'''''||'''''Overview'''''|| ||YA | + | |'''''T-Lymphoblastic Leukemia/Lymphoma'''''||'''''Overview'''''|| |
| + | | ||YA |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |Early T-Cell Precursor Lymphoblastic Leukemia||Disease|| ||YA | + | |Early T-Cell Precursor Lymphoblastic Leukemia||Disease|| |
| + | | ||YA |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |NK-Lymphoblastic Leukemia/Lymphoma||Disease|| ||YA | + | |NK-Lymphoblastic Leukemia/Lymphoma||Disease|| |
| + | | ||YA |
| | | | | |
| | | | | |
Line 569: |
Line 669: |
| |Disease | | |Disease |
| |Helene Bruyere | | |Helene Bruyere |
| + | | |
| |YA | | |YA |
| |PENDING | | |PENDING |
Line 574: |
Line 675: |
| |NON-WHO ENTITY | | |NON-WHO ENTITY |
| |- | | |- |
− | | || || || | + | | || || |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |'''''Mature B-Cell Neoplasms'''''||'''''Overview'''''|| ||Snehal Patel (SP) | + | |'''''Mature B-Cell Neoplasms'''''||'''''Overview'''''|| |
| + | | ||Snehal Patel (SP) |
| | | | | |
| | | | | |
Line 585: |
Line 688: |
| |- | | |- |
| |Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Disease||Honey Reddi | | |Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Disease||Honey Reddi |
| + | | |
| |SP | | |SP |
| |PENDING | | |PENDING |
Line 591: |
Line 695: |
| |- | | |- |
| | Monoclonal B-cell Lymphocytosis||Disease||Honey Reddi | | | Monoclonal B-cell Lymphocytosis||Disease||Honey Reddi |
| + | | |
| |SP | | |SP |
| |PENDING | | |PENDING |
Line 597: |
Line 702: |
| |- | | |- |
| |B-cell Prolymphocytic Leukemia||Disease||Honey Reddi | | |B-cell Prolymphocytic Leukemia||Disease||Honey Reddi |
| + | | |
| |SP | | |SP |
| |PENDING | | |PENDING |
Line 603: |
Line 709: |
| |- | | |- |
| |Splenic Marginal Zone Lymphoma||Disease||Snehal Patel | | |Splenic Marginal Zone Lymphoma||Disease||Snehal Patel |
| + | | |
| |SP | | |SP |
| |Complete | | |Complete |
Line 609: |
Line 716: |
| |- | | |- |
| |Hairy Cell Leukemia||Disease||Snehal Patel | | |Hairy Cell Leukemia||Disease||Snehal Patel |
| + | | |
| |SP | | |SP |
| |Complete | | |Complete |
Line 615: |
Line 723: |
| |- | | |- |
| |'''''Splenic B-cell Lymphoma/Leukemia, Unclassifiable'''''||'''''Overview'''''||Snehal Patel | | |'''''Splenic B-cell Lymphoma/Leukemia, Unclassifiable'''''||'''''Overview'''''||Snehal Patel |
| + | | |
| |SP | | |SP |
| |Complete | | |Complete |
Line 621: |
Line 730: |
| |- | | |- |
| | Splenic Diffuse Red Pulp Small B-cell Lymphoma||Disease||Snehal Patel | | | Splenic Diffuse Red Pulp Small B-cell Lymphoma||Disease||Snehal Patel |
| + | | |
| |SP | | |SP |
| |Complete | | |Complete |
Line 627: |
Line 737: |
| |- | | |- |
| | Hairy Cell Leukemia Variant||Disease||Snehal Patel | | | Hairy Cell Leukemia Variant||Disease||Snehal Patel |
| + | | |
| |SP | | |SP |
| |Complete | | |Complete |
Line 633: |
Line 744: |
| |- | | |- |
| |Lymphoplasmacytic Lymphoma||Disease||Honey Reddi | | |Lymphoplasmacytic Lymphoma||Disease||Honey Reddi |
| + | | |
| |SP | | |SP |
| |PENDING | | |PENDING |
Line 639: |
Line 751: |
| |- | | |- |
| | Waldenstrom Macroglobulinemia||Disease||Honey Reddi | | | Waldenstrom Macroglobulinemia||Disease||Honey Reddi |
| + | | |
| |SP | | |SP |
| |PENDING | | |PENDING |
Line 644: |
Line 757: |
| | | | | |
| |- | | |- |
− | |IgM Monoclonal Gammopathy of Undetermined Significance||Disease|| ||SP | + | |IgM Monoclonal Gammopathy of Undetermined Significance||Disease|| |
| + | | ||SP |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |'''''Heavy Chain Diseases'''''||'''''Overview'''''|| ||SP | + | |'''''Heavy Chain Diseases'''''||'''''Overview'''''|| |
| + | | ||SP |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | Mu Heavy Chain Disease||Disease|| ||SP | + | | Mu Heavy Chain Disease||Disease|| |
| + | | ||SP |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | Gamma Heavy Chain Disease||Disease|| ||SP | + | | Gamma Heavy Chain Disease||Disease|| |
| + | | ||SP |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | Alpha Heavy Chain Disease||Disease|| ||SP | + | | Alpha Heavy Chain Disease||Disease|| |
| + | | ||SP |
| | | | | |
| | | | | |
Line 670: |
Line 788: |
| |- | | |- |
| |Plasma Cell Neoplasms||'''''Overview'''''||Zhenya Tang | | |Plasma Cell Neoplasms||'''''Overview'''''||Zhenya Tang |
| + | | |
| |SP | | |SP |
| |PENDING | | |PENDING |
Line 676: |
Line 795: |
| |- | | |- |
| | Non-IgM Monoclonal Gammopathy of Undetermined Significance||Disease||Zhenya Tang | | | Non-IgM Monoclonal Gammopathy of Undetermined Significance||Disease||Zhenya Tang |
| + | | |
| |SP | | |SP |
| |PENDING | | |PENDING |
Line 682: |
Line 802: |
| |- | | |- |
| | Plasma Cell Myeloma||Disease||Zhenya Tang/Huang Mo (trainee) | | | Plasma Cell Myeloma||Disease||Zhenya Tang/Huang Mo (trainee) |
| + | | |
| |SP | | |SP |
| |PENDING | | |PENDING |
Line 688: |
Line 809: |
| |- | | |- |
| | Plasma Cell Myeloma Variants||Disease||Zhenya Tang | | | Plasma Cell Myeloma Variants||Disease||Zhenya Tang |
| + | | |
| |SP | | |SP |
| |PENDING | | |PENDING |
Line 694: |
Line 816: |
| |- | | |- |
| | Plasmacytoma||Disease||Zhenya Tang | | | Plasmacytoma||Disease||Zhenya Tang |
| + | | |
| |SP | | |SP |
| |PENDING | | |PENDING |
Line 699: |
Line 822: |
| | | | | |
| |- | | |- |
− | |''''' Monoclonal Immunoglobulin Deposition Diseases'''''||'''''Overview'''''|| ||SP | + | |''''' Monoclonal Immunoglobulin Deposition Diseases'''''||'''''Overview'''''|| |
| + | | ||SP |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | Primary Amyloidosis||Disease|| ||SP | + | | Primary Amyloidosis||Disease|| |
| + | | ||SP |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | Light Chain and Heavy Chain Deposition Disease||Disease|| ||SP | + | | Light Chain and Heavy Chain Deposition Disease||Disease|| |
| + | | ||SP |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''|| ||SP | + | |'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''|| |
| + | | ||SP |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | POEMS Syndrome||Disease|| ||SP | + | | POEMS Syndrome||Disease|| |
| + | | ||SP |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | TEMPI Syndrome||Disease|| ||SP | + | | TEMPI Syndrome||Disease|| |
| + | | ||SP |
| | | | | |
| | | | | |
Line 730: |
Line 859: |
| |- | | |- |
| |Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)||Disease||Zhenya Tang & Trainee | | |Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)||Disease||Zhenya Tang & Trainee |
| + | | |
| |SP | | |SP |
| |PENDING | | |PENDING |
Line 735: |
Line 865: |
| | | | | |
| |- | | |- |
− | |Nodal Marginal Zone Lymphoma||Disease|| ||SP | + | |Nodal Marginal Zone Lymphoma||Disease|| |
| + | | ||SP |
| | | | | |
| | | | | |
Line 741: |
Line 872: |
| |- | | |- |
| | Paediatric Nodal Marginal Zone Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee) | | | Paediatric Nodal Marginal Zone Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee) |
| + | | |
| |SP | | |SP |
| |PENDING | | |PENDING |
Line 747: |
Line 879: |
| |- | | |- |
| |Follicular Lymphoma||Disease||Ruthann Pfau | | |Follicular Lymphoma||Disease||Ruthann Pfau |
| + | | |
| |SP | | |SP |
| |PENDING | | |PENDING |
Line 753: |
Line 886: |
| |- | | |- |
| | Testicular Follicular Lymphoma||Disease||Ruthann Pfau | | | Testicular Follicular Lymphoma||Disease||Ruthann Pfau |
| + | | |
| |SP | | |SP |
| |PENDING | | |PENDING |
Line 759: |
Line 893: |
| |- | | |- |
| | In Situ Follicular Neoplasia||Disease||Ruthann Pfau | | | In Situ Follicular Neoplasia||Disease||Ruthann Pfau |
| + | | |
| |SP | | |SP |
| |PENDING | | |PENDING |
Line 765: |
Line 900: |
| |- | | |- |
| | Duodenal-Type Follicular Lymphoma||Disease||Ruthann Pfau | | | Duodenal-Type Follicular Lymphoma||Disease||Ruthann Pfau |
| + | | |
| |SP | | |SP |
| |PENDING | | |PENDING |
Line 771: |
Line 907: |
| |- | | |- |
| |Paediatric-Type Follicular Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee) | | |Paediatric-Type Follicular Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee) |
| + | | |
| |SP | | |SP |
| |PENDING | | |PENDING |
Line 776: |
Line 913: |
| | | | | |
| |- | | |- |
− | |Large B-cell Lymphoma with IRF4 Rearrangement||Disease|| ||SP | + | |Large B-cell Lymphoma with IRF4 Rearrangement||Disease|| |
| + | | ||SP |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |Primary Cutaneous Follicle Centre Lymphoma||Disease|| ||SP | + | |Primary Cutaneous Follicle Centre Lymphoma||Disease|| |
| + | | ||SP |
| | | | | |
| | | | | |
Line 787: |
Line 926: |
| |- | | |- |
| |Mantle Cell Lymphoma||Disease||Mahsa Khanlari | | |Mantle Cell Lymphoma||Disease||Mahsa Khanlari |
| + | | |
| |SP | | |SP |
| |PENDING - due 8/15/20 | | |PENDING - due 8/15/20 |
Line 793: |
Line 933: |
| |- | | |- |
| | Leukemic Non-Nodal Mantle Cell Lymphoma||Disease||Mahsa Khanlari | | | Leukemic Non-Nodal Mantle Cell Lymphoma||Disease||Mahsa Khanlari |
| + | | |
| |SP | | |SP |
| |PENDING - due 8/31/20 | | |PENDING - due 8/31/20 |
Line 799: |
Line 940: |
| |- | | |- |
| | In Situ Mantle Cell Neoplasia||Disease||Mahsa Khanlari | | | In Situ Mantle Cell Neoplasia||Disease||Mahsa Khanlari |
| + | | |
| |SP | | |SP |
| |PENDING - due 8/15/20 | | |PENDING - due 8/15/20 |
Line 804: |
Line 946: |
| | | | | |
| |- | | |- |
− | | || || || | + | | || || |
| + | | || |
| | | | | |
| | | | | |
Line 810: |
Line 953: |
| |- | | |- |
| |Diffuse Large B-cell Lymphoma, Not Otherwise Specified||Disease||Ashwini Yenamandra | | |Diffuse Large B-cell Lymphoma, Not Otherwise Specified||Disease||Ashwini Yenamandra |
| + | | |
| |Greg Corboy (GC) | | |Greg Corboy (GC) |
| |PENDING | | |PENDING |
Line 815: |
Line 959: |
| | | | | |
| |- | | |- |
− | |T-cell/Histiocyte-Rich Large B-cell Lymphoma||Disease|| ||GC | + | |T-cell/Histiocyte-Rich Large B-cell Lymphoma||Disease|| |
| + | | ||GC |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |Primary Diffuse Large B-cell Lymphoma of the CNS||Disease|| ||GC | + | |Primary Diffuse Large B-cell Lymphoma of the CNS||Disease|| |
| + | | ||GC |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type||Disease|| ||GC | + | |Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type||Disease|| |
| + | | ||GC |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |EBV-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease|| ||GC | + | |EBV-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease|| |
| + | | ||GC |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |EBV-Positive Mucocutaneous Ulcer||Disease|| ||GC | + | |EBV-Positive Mucocutaneous Ulcer||Disease|| |
| + | | ||GC |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |Diffuse Large B-cell Lymphoma Associated with Chronic Inflammation||Disease|| ||GC | + | |Diffuse Large B-cell Lymphoma Associated with Chronic Inflammation||Disease|| |
| + | | ||GC |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | Fibrin-Associated Diffuse Large B-cell Lymphoma||Disease|| ||GC | + | | Fibrin-Associated Diffuse Large B-cell Lymphoma||Disease|| |
| + | | ||GC |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |Lymphomatoid Granulomatosis||Disease|| ||GC | + | |Lymphomatoid Granulomatosis||Disease|| |
| + | | ||GC |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |Primary Mediastinal (Thymic) Large B-cell Lymphoma||Disease|| ||GC | + | |Primary Mediastinal (Thymic) Large B-cell Lymphoma||Disease|| |
| + | | ||GC |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |Intravascular Large B-cell Lymphoma||Disease|| ||GC | + | |Intravascular Large B-cell Lymphoma||Disease|| |
| + | | ||GC |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |ALK-Positive Large B-cell Lymphoma||Disease|| ||GC | + | |ALK-Positive Large B-cell Lymphoma||Disease|| |
| + | | ||GC |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |Plasmablastic Lymphoma||Disease||Mark Evans (trainee), Fabiola Quintero-Rivera||GC | + | |Plasmablastic Lymphoma||Disease||Mark Evans (trainee), Fabiola Quintero-Rivera |
| + | | ||GC |
| |Complete | | |Complete |
| | | | | |
| | | | | |
| |- | | |- |
− | |Primary Effusion Lymphoma||Disease|| ||GC | + | |Primary Effusion Lymphoma||Disease|| |
| + | | ||GC |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |'''''HHV8-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''|| ||GC | + | |'''''HHV8-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''|| |
| + | | ||GC |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | Multicentric Castleman Disease||Disease|| ||GC | + | | Multicentric Castleman Disease||Disease|| |
| + | | ||GC |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | HHV8-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease|| ||GC | + | | HHV8-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease|| |
| + | | ||GC |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | HHV8-Positive Germinotropic Lymphoproliferative Disorder||Disease|| ||GC | + | | HHV8-Positive Germinotropic Lymphoproliferative Disorder||Disease|| |
| + | | ||GC |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |Burkitt Lymphoma||Disease|| ||GC | + | |Burkitt Lymphoma||Disease|| |
| + | | ||GC |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |Burkitt-Like Lymphoma with 11q Aberration||Disease|| ||GC | + | |Burkitt-Like Lymphoma with 11q Aberration||Disease|| |
| + | | ||GC |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |'''''High-Grade B-cell Lymphoma'''''||'''''Overview'''''|| ||GC | + | |'''''High-Grade B-cell Lymphoma'''''||'''''Overview'''''|| |
| + | | ||GC |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements||Disease|| ||GC | + | | High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements||Disease|| |
| + | | ||GC |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease|| ||GC | + | | High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease|| |
| + | | ||GC |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |B-cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma||Disease|| ||GC | + | |B-cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma||Disease|| |
| + | | ||GC |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | || || || | + | | || || |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |'''''Mature T- and NK-cell Neoplasms'''''||'''''Overview'''''|| ||Snehal Patel (SP) | + | |'''''Mature T- and NK-cell Neoplasms'''''||'''''Overview'''''|| |
| + | | ||Snehal Patel (SP) |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |T-cell Prolymphocytic Leukemia||Disease||Michelle Don||SP | + | |T-cell Prolymphocytic Leukemia||Disease||Michelle Don |
| + | | ||SP |
| |PENDING | | |PENDING |
| | | | | |
| | | | | |
| |- | | |- |
− | |T-cell Large Granular Lymphocytic Leukemia||Disease||Michelle Don||SP | + | |T-cell Large Granular Lymphocytic Leukemia||Disease||Michelle Don |
| + | | ||SP |
| |PENDING | | |PENDING |
| | | | | |
| | | | | |
| |- | | |- |
− | |Chronic Lymphoproliferative Disorder of NK Cells||Disease||Michelle Don||SP | + | |Chronic Lymphoproliferative Disorder of NK Cells||Disease||Michelle Don |
| + | | ||SP |
| |PENDING | | |PENDING |
| | | | | |
| | | | | |
| |- | | |- |
− | |Aggressive NK-cell Leukemia||Disease|| ||SP | + | |Aggressive NK-cell Leukemia||Disease|| |
| + | | ||SP |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |'''''EBV-Positive T-cell and NK-cell Lymphoproliferative Diseases of Childhood'''''||'''''Overview'''''|| ||SP | + | |'''''EBV-Positive T-cell and NK-cell Lymphoproliferative Diseases of Childhood'''''||'''''Overview'''''|| |
| + | | ||SP |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | Systemic EBV-Positive T-cell Lymphoma of Childhood||Disease|| ||SP | + | | Systemic EBV-Positive T-cell Lymphoma of Childhood||Disease|| |
| + | | ||SP |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | Chronic Active EBV Infection of T- and NK-cell Type, Systemic Form||Disease|| ||SP | + | | Chronic Active EBV Infection of T- and NK-cell Type, Systemic Form||Disease|| |
| + | | ||SP |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | Hydroa Vacciniforme-Like Lymphoproliferative Disorder||Disease|| ||SP | + | | Hydroa Vacciniforme-Like Lymphoproliferative Disorder||Disease|| |
| + | | ||SP |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | Severe Mosquito Bite Allergy||Disease|| ||SP | + | | Severe Mosquito Bite Allergy||Disease|| |
| + | | ||SP |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |Adult T-cell Leukemia/Lymphoma||Disease|| ||SP | + | |Adult T-cell Leukemia/Lymphoma||Disease|| |
| + | | ||SP |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |Extranodal NK/T-cell Lymphoma, Nasal Type||Disease|| ||SP | + | |Extranodal NK/T-cell Lymphoma, Nasal Type||Disease|| |
| + | | ||SP |
| | | | | |
| | | | | |
Line 996: |
Line 1,176: |
| |- | | |- |
| |'''''Intestinal T-cell Lymphoma'''''||'''''Overview'''''||Sumire Kitahara, Derick Okwan (trainee) | | |'''''Intestinal T-cell Lymphoma'''''||'''''Overview'''''||Sumire Kitahara, Derick Okwan (trainee) |
| + | | |
| |SP | | |SP |
| |PENDING | | |PENDING |
Line 1,002: |
Line 1,183: |
| |- | | |- |
| | Enteropathy-Associated T-cell Lymphoma||Disease||Sumire Kitahara, Derick Okwan (trainee) | | | Enteropathy-Associated T-cell Lymphoma||Disease||Sumire Kitahara, Derick Okwan (trainee) |
| + | | |
| |SP | | |SP |
| |PENDING | | |PENDING |
Line 1,008: |
Line 1,190: |
| |- | | |- |
| | Monomorphic Epitheliotropic Intestinal T-cell Lymphoma||Disease||Sumire Kitahara | | | Monomorphic Epitheliotropic Intestinal T-cell Lymphoma||Disease||Sumire Kitahara |
| + | | |
| |SP | | |SP |
| |PENDING | | |PENDING |
Line 1,014: |
Line 1,197: |
| |- | | |- |
| | Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||Sumire Kitahara, Derick Okwan (trainee) | | | Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||Sumire Kitahara, Derick Okwan (trainee) |
| + | | |
| |SP | | |SP |
| |PENDING | | |PENDING |
Line 1,020: |
Line 1,204: |
| |- | | |- |
| | Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract||Disease||Sumire Kitahara, Derick Okwan (trainee) | | | Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract||Disease||Sumire Kitahara, Derick Okwan (trainee) |
| + | | |
| |SP | | |SP |
| |PENDING | | |PENDING |
Line 1,025: |
Line 1,210: |
| | | | | |
| |- | | |- |
− | |Hepatosplenic T-cell Lymphoma||Disease||Michelle Don||SP | + | |Hepatosplenic T-cell Lymphoma||Disease||Michelle Don |
| + | | ||SP |
| |PENDING | | |PENDING |
| | | | | |
| | | | | |
| |- | | |- |
− | |Subcutaneous Panniculitis-Like T-cell Lymphoma||Disease|| ||SP | + | |Subcutaneous Panniculitis-Like T-cell Lymphoma||Disease|| |
| + | | ||SP |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |Mycosis Fungoides||Disease|| ||SP | + | |Mycosis Fungoides||Disease|| |
| + | | ||SP |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |Sézary Syndrome||Disease|| ||SP | + | |Sézary Syndrome||Disease|| |
| + | | ||SP |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |'''''Primary Cutaneous CD30 Positive T-cell Lymphoproliferative Disorders'''''||'''''Overview'''''|| ||SP | + | |'''''Primary Cutaneous CD30 Positive T-cell Lymphoproliferative Disorders'''''||'''''Overview'''''|| |
| + | | ||SP |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | Lymphomatoid Papulosis||Disease|| ||SP | + | | Lymphomatoid Papulosis||Disease|| |
| + | | ||SP |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | Primary Cutaneous Anaplastic Large Cell Lymphoma||Disease|| ||SP | + | | Primary Cutaneous Anaplastic Large Cell Lymphoma||Disease|| |
| + | | ||SP |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |'''''Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes'''''||'''''Overview'''''|| ||SP | + | |'''''Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes'''''||'''''Overview'''''|| |
| + | | ||SP |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | Primary Cutaneous Gamma Delta T-cell Lymphoma||Disease|| ||SP | + | | Primary Cutaneous Gamma Delta T-cell Lymphoma||Disease|| |
| + | | ||SP |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma||Disease|| ||SP | + | | Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma||Disease|| |
| + | | ||SP |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | Primary Cutaneous Acral CD8+ T-cell Lymphoma||Disease|| ||SP | + | | Primary Cutaneous Acral CD8+ T-cell Lymphoma||Disease|| |
| + | | ||SP |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | Primary Cutaneous CD4+ Small/Medium T-cell Lymphoproliferative Disorder||Disease|| ||SP | + | | Primary Cutaneous CD4+ Small/Medium T-cell Lymphoproliferative Disorder||Disease|| |
| + | | ||SP |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |Peripheral T-cell Lymphoma, Not Otherwise Specified (NOS)||Disease|| ||SP | + | |Peripheral T-cell Lymphoma, Not Otherwise Specified (NOS)||Disease|| |
| + | | ||SP |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |'''''Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of T Follicular Helper Cell Origin'''''||'''''Overview'''''|| ||SP | + | |'''''Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of T Follicular Helper Cell Origin'''''||'''''Overview'''''|| |
| + | | ||SP |
| | | | | |
| | | | | |
Line 1,096: |
Line 1,295: |
| |- | | |- |
| | Angioimmunoblastic T-cell Lymphoma||Disease||Ruthann Pfau, Sara Akhavanfard (trainee) | | | Angioimmunoblastic T-cell Lymphoma||Disease||Ruthann Pfau, Sara Akhavanfard (trainee) |
| + | | |
| |SP | | |SP |
| |PENDING | | |PENDING |
Line 1,102: |
Line 1,302: |
| |- | | |- |
| | Follicular T-cell Lymphoma||Disease||Ruthann Pfau, Sara Akhavanfard (trainee) | | | Follicular T-cell Lymphoma||Disease||Ruthann Pfau, Sara Akhavanfard (trainee) |
| + | | |
| |SP | | |SP |
| |PENDING | | |PENDING |
Line 1,107: |
Line 1,308: |
| | | | | |
| |- | | |- |
− | | Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype||Disease|| ||SP | + | | Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype||Disease|| |
| + | | ||SP |
| | | | | |
| | | | | |
Line 1,113: |
Line 1,315: |
| |- | | |- |
| |Anaplastic Large Cell Lymphoma, ALK-Positive||Disease||Sumire Kitahara | | |Anaplastic Large Cell Lymphoma, ALK-Positive||Disease||Sumire Kitahara |
| + | | |
| |SP | | |SP |
| |PENDING | | |PENDING |
Line 1,119: |
Line 1,322: |
| |- | | |- |
| |Anaplastic Large Cell Lymphoma, ALK-Negative||Disease||Sumire Kitahara | | |Anaplastic Large Cell Lymphoma, ALK-Negative||Disease||Sumire Kitahara |
| + | | |
| |SP | | |SP |
| |PENDING | | |PENDING |
Line 1,125: |
Line 1,329: |
| |- | | |- |
| |Breast Implant-Associated Anaplastic Large Cell Lymphoma||Disease||Sumire Kitahara | | |Breast Implant-Associated Anaplastic Large Cell Lymphoma||Disease||Sumire Kitahara |
| + | | |
| |SP | | |SP |
| |PENDING | | |PENDING |
Line 1,130: |
Line 1,335: |
| | | | | |
| |- | | |- |
− | | || || || | + | | || || |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |'''''Hodgkin Lymphomas'''''||'''''Overview'''''|| ||Associate Editor?? | + | |'''''Hodgkin Lymphomas'''''||'''''Overview'''''|| |
| + | | ||Associate Editor?? |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |Nodular Lymphocyte Predominant Hodgkin Lymphoma||Disease|| || | + | |Nodular Lymphocyte Predominant Hodgkin Lymphoma||Disease|| |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |'''''Classic Hodgkin Lymphoma'''''||'''''Overview'''''|| || | + | |'''''Classic Hodgkin Lymphoma'''''||'''''Overview'''''|| |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | Nodular Sclerosis Classic Hodgkin Lymphoma||Disease|| || | + | | Nodular Sclerosis Classic Hodgkin Lymphoma||Disease|| |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | Lymphocyte-Rich Classic Hodgkin Lymphoma||Disease|| || | + | | Lymphocyte-Rich Classic Hodgkin Lymphoma||Disease|| |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | Mixed Cellularity Classic Hodgkin Lymphoma||Disease|| || | + | | Mixed Cellularity Classic Hodgkin Lymphoma||Disease|| |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | Lymphocyte-Depleted Classic Hodgkin Lymphoma||Disease|| || | + | | Lymphocyte-Depleted Classic Hodgkin Lymphoma||Disease|| |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |'''''Immunodeficiency-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''|| || | + | |'''''Immunodeficiency-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''|| |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |Lymphomas Associated with HIV Infection||Disease|| || | + | |Lymphomas Associated with HIV Infection||Disease|| |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |'''''Post-Transplant Lymphoproliferative Disorders'''''||'''''Overview'''''|| || | + | |'''''Post-Transplant Lymphoproliferative Disorders'''''||'''''Overview'''''|| |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | Non-Destructive Post-Transplant Lymphoproliferative Disorders||Disease|| || | + | | Non-Destructive Post-Transplant Lymphoproliferative Disorders||Disease|| |
| + | | || |
| | | | | |
| | | | | |
Line 1,193: |
Line 1,410: |
| | | |
| Fabiola Quintero-Rivera | | Fabiola Quintero-Rivera |
| + | | |
| | | | | |
| |PENDING | | |PENDING |
Line 1,198: |
Line 1,416: |
| | | | | |
| |- | | |- |
− | |''''' Monomorphic Post-Transplant Lymphoproliferative Disorders (B- and T/NK-cell Types)'''''||'''''Overview'''''|| || | + | |''''' Monomorphic Post-Transplant Lymphoproliferative Disorders (B- and T/NK-cell Types)'''''||'''''Overview'''''|| |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | Monomorphic B-cell PTLD||Disease|| || | + | | Monomorphic B-cell PTLD||Disease|| |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | Monomorphic T/NK-cell PTLD||Disease|| || | + | | Monomorphic T/NK-cell PTLD||Disease|| |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | Classical Hodgkin Lymphoma Post-Transplant Lymphoproliferative Disorder||Disease|| || | + | | Classical Hodgkin Lymphoma Post-Transplant Lymphoproliferative Disorder||Disease|| |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders||Disease|| || | + | |Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders||Disease|| |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |'''''Histiocytic and Dendritic Cell Neoplasms'''''||'''''Overview'''''|| || | + | |'''''Histiocytic and Dendritic Cell Neoplasms'''''||'''''Overview'''''|| |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |Histiocytic Sarcoma||Disease|| || | + | |Histiocytic Sarcoma||Disease|| |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |'''''Tumors Derived From Langerhans Cells'''''||'''''Overview'''''|| || | + | |'''''Tumors Derived From Langerhans Cells'''''||'''''Overview'''''|| |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | Langerhans Cell Histiocytosis||Disease|| || | + | | Langerhans Cell Histiocytosis||Disease|| |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | Langerhans Cell Sarcoma||Disease|| || | + | | Langerhans Cell Sarcoma||Disease|| |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |Indeterminate Dendritic Cell Tumour||Disease|| || | + | |Indeterminate Dendritic Cell Tumour||Disease|| |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |Interdigitating Dendritic Cell Sarcoma||Disease|| || | + | |Interdigitating Dendritic Cell Sarcoma||Disease|| |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |Follicular Dendritic Cell Sarcoma||Disease|| || | + | |Follicular Dendritic Cell Sarcoma||Disease|| |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | Inflammatory Pseudotumor-Like Follicular/Fibroblastic Dendritic Cell Sarcoma||Disease|| || | + | | Inflammatory Pseudotumor-Like Follicular/Fibroblastic Dendritic Cell Sarcoma||Disease|| |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |Fibroblastic Reticular Cell Tumor||Disease|| || | + | |Fibroblastic Reticular Cell Tumor||Disease|| |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |Disseminated Juvenile Xanthogranuloma||Disease|| || | + | |Disseminated Juvenile Xanthogranuloma||Disease|| |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | |Erdheim-Chester Disease||Disease|| || | + | |Erdheim-Chester Disease||Disease|| |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | || || || | + | | || || |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | || || || | + | | || || |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | || || || | + | | || || |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | || || || | + | | || || |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | || || || | + | | || || |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | || || || | + | | || || |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | || || || | + | | || || |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | || || || | + | | || || |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | || || || | + | | || || |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | || || || | + | | || || |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | || || || | + | | || || |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | || || || | + | | || || |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | || || || | + | | || || |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | || || || | + | | || || |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | || || || | + | | || || |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | || || || | + | | || || |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | || || || | + | | || || |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | || || || | + | | || || |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | || || || | + | | || || |
| + | | || |
| | | | | |
| | | | | |
| | | | | |
| |- | | |- |
− | | || || || | + | | || || |
| + | | || |
| | | | | |
| | | | | |